Save Product
Product Details
Synonym
TNFRSF17, CD269, BCM, BCMA
Source
FITC-Labeled Human BCMA, His Tag (BCA-HF2H1) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Ala 54 (Accession # Q02223-1). It is the FITC labeled form of Human BCMA, His Tag.
Predicted N-terminus: Met 1
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 7.79 kDa. The protein migrates as 10 kDa and 14-16 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Conjugate
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
Labeling
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.
Protein Ratio
The FITC to protein molar ratio is 1-3.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
FITC-Labeled Human BCMA, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Evaluation of CAR expression
FACS Analysis of Anti-BCMA CAR Expression
293 cells were transfected with anti-BCMA-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H1, 1 µg/ml) and C. FITC-labeled protein control. A. Non-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-BCMA-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human BCMA, His Tag (Cat. No. BCA-HF2H1) (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
B-cell maturation protein
- Category：
- Approved Drugs：
7 Details
- Drugs in Clinical Trials：
117 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing